News
EQS-Adhoc: ACCENTRO and bondholders agreed on extension of current bridge notes and an additional bridge funding as part of the ongoing restructuring negotiations
EQS-Adhoc: ACCENTRO and bondholders agreed on extension of current bridge notes and an additional bridge funding as part of the ongoing restructuring negotiations
EQS-News: USU Secures New US Customer for Software Asset Management
EQS-News: USU Secures New US Customer for Software Asset Management
EQS-Adhoc: MBB beats its 2024 guidance with revenues of €1.06 billion at an EBITDA margin of more than 13% based on preliminary figures and announces management changes
EQS-Adhoc: MBB beats its 2024 guidance with revenues of €1.06 billion at an EBITDA margin of more than 13% based on preliminary figures and announces management changes
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-News: Mynaric Announces Receipt of Deficiency Letters from Nasdaq
EQS-News: Mynaric Announces Receipt of Deficiency Letters from Nasdaq
EQS-News: Heliad: Nelly raises EUR 50m in Series B funding to revolutionize financial operations in healthcare
EQS-News: Heliad: Nelly raises EUR 50m in Series B funding to revolutionize financial operations in healthcare
EQS-News: Allane Mobility Group electrifies fleet of major customer and sets standards for sustainable mobility
EQS-News: Allane Mobility Group electrifies fleet of major customer and sets standards for sustainable mobility
EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
EQS-News: Starting Signal for USU Digital Consulting: Shaping the Future and Driving Digitalization Forward
EQS-News: Starting Signal for USU Digital Consulting: Shaping the Future and Driving Digitalization Forward
EQS-Adhoc: STEICO SE: unaudited business figures for 2024: revenue of € 376.3 million, EBIT of € 36.1 million
EQS-Adhoc: STEICO SE: unaudited business figures for 2024: revenue of € 376.3 million, EBIT of € 36.1 million
Swiss companies confirm medium-term revenue targets at Baader Helvea Swiss Equities Conference 2025
Swiss companies confirm medium-term revenue targets at Baader Helvea Swiss Equities Conference 2025
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Manz AG provides information on the current status of the preliminary insolvency proceedings
EQS-News: Manz AG provides information on the current status of the preliminary insolvency proceedings
FRoSTA AG veröffentlicht vorläufige Finanzkennzahlen für das Geschäftsjahr 2024 – Konzernjahresüberschuss übertrifft Prognose durch starke Nachfrage nach der Marke FRoSTA
FRoSTA AG veröffentlicht vorläufige Finanzkennzahlen für das Geschäftsjahr 2024 – Konzernjahresüberschuss übertrifft Prognose durch starke Nachfrage nach der Marke FRoSTA
EQS-Adhoc: DATAGROUP will not pursue the spin-off of its subsidiary Almato AG
EQS-Adhoc: DATAGROUP will not pursue the spin-off of its subsidiary Almato AG
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
EQS-News: Formycon included in TecDAX Index of Deutsche Börse
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Elmos and ID Quantique join forces to develop the world's smallest Quantum Random Number Generator (QRNG) solution
EQS-News: Elmos and ID Quantique join forces to develop the world's smallest Quantum Random Number Generator (QRNG) solution
EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 4th Interim Report
EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 4th Interim Report
EQS-News: Elmos Semiconductor SE: Expansion of collaboration with foundry partner Samsung Foundry
EQS-News: Elmos Semiconductor SE: Expansion of collaboration with foundry partner Samsung Foundry
EQS-Adhoc: MEDION AG: Entry of the Transfer Decision in the Commercial Register
EQS-Adhoc: MEDION AG: Entry of the Transfer Decision in the Commercial Register
EQS-Adhoc: Mynaric Updates Guidance on 2024 Key Performance Indicators, Lowering Revenue and Optical Communications Terminal Backlog Guidance
EQS-Adhoc: Mynaric Updates Guidance on 2024 Key Performance Indicators, Lowering Revenue and Optical Communications Terminal Backlog Guidance